Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression

Nature Reviews Neurology

Volumn 6, Issue 3, 2010, Pages 126-128

  Sampaio, Cristina ^a   Ferreira, Joaquim J ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

RASAGILINE;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SHORT SURVEY;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; INDANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TIME FACTORS;

EID: 77949378919     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.2     Document Type: Short Survey

References (9)

1. Rascol, O., Goetz, C., Koller, w., Poewe, w. & sampaio, C. Treatment interventions for Parkinsons disease: an evidence based assessment. Lancet 359, 1589-1598 (2002).
2. Olanow, C. w. et al. A double-blind, delayedstart trial of rasagiline in Parkinsons disease. N. Engl. J. Med. 361, 1268-1278 (2009).
3. Macleod, A. D., Counsell, C. e., ives, n. & stowe, R. Monoamine oxidase B inhibitors for early Parkinsons disease. Cochrane Database of Systematic Reviews, issue 3. Art. no.: CD004898. doi:10.1002/14651858. CD004898.pub2 (2005).
4. Mandel, s., weinreb, O., Amit, T. & Youdim, M. B. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 48, 379-387 (2005).
5. Parkinson study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566 (2004).
6. Hauser, R. A. et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinsons disease. Mov. Disord. 24, 564-573 (2009).
7. Marek, K., Jennings, D., Tamagnan, G. & seibyl, J. Biomarkers for Parkinsons [corrected] disease: tools to assess Parkinsons disease onset and progression. Ann. Neurol. 64 (suppl. 2), s111-s121 (2008).
8. Leber, P. slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis. Assoc. Disord. 11 (suppl. 5), s10-s21 (1997).
9. DAgostino, R. B. The delayed-start study design. N. Engl. J. Med. 361, 1304-1306 (2009).